title: Semiconductor chips, genes, and stem cells: new wine for new bottles?
abstract: This Article analogizes early semiconductor technology and its surrounding economics with isolated genes, stem cells, and related bioproducts, and their surrounding economics, to make the case for sui generis (of its own class) intellectual property protection for isolated bioproducts. Just as early semiconductors failed to meet the patent social bargain requiring novelty and non-obviousness in the 1980s, isolated genes and stem cells currently fail to meet the patent bargain requirements of non-obviousness and eligible subject matter that entitle them to traditional intellectual property protection. Like early semiconductor chip designs, nevertheless, the high cost of upstream bioproduct research and development, coupled with the need to sustain continued economic growth of the biotechnology industry, mandates that Congress provide some level of exclusive rights to ensure continued funding for this research. Sui generis intellectual property protection for isolated bioproducts would preserve the incentive to continue innovation in the field. As illustrated by the semiconductor industry, however, such sui generis protection for this technology must include limitations that address the need to provide an appropriate level of public access to facilitate downstream product development and enrich the public domain.
authors.affiliation: Wake Forest University, USA.
authors.forename: Simone A
authors.initials: SA
authors.lastname: Rose
mesh_terms: D001709:Biotechnology / Q000331:legislation & jurisprudence; D003132:Commerce / Q000331:legislation & jurisprudence; D019398:Genes, BRCA1; D024522:Genes, BRCA2; D005820:Genetic Testing / Q000331:legislation & jurisprudence*; D006801:Humans; D018973:Intellectual Property; D012666:Semiconductors; D057905:Stem Cell Research / Q000331:legislation & jurisprudence*; D013234:Stem Cells / Q000166:cytology*; D014481:United States